Tango Therapeutics stock performance in 2026

What happened: Tango Therapeutics (TNGX) stock surged in 2026, driven by positive data announcements and increased investor confidence. On May 15, Leerink raised its price target to $55, following the company's Q1 results. RTW Investments added 11.8 million shares, investing approximately $164 million. Stifel also boosted its price target to $40, citing conviction in Tango's PRMT5 inhibitor.

Market impact: The healthcare sector, particularly biotechnology, witnessed increased activity. Tango Therapeutics, one of the most promising mid-cap healthcare stocks, saw its valuation repriced higher. This attracted significant institutional investment, with RTW Investments' move alone adding over $265 million to Tango's market capitalization.

What to watch next: Tango Therapeutics' upcoming catalysts include its Q2 earnings release (scheduled for August 15), potential updates on its PRMT5 inhibitor's clinical trials, and any further price target revisions from analysts. Additionally, investors should monitor any regulatory decisions related to Tango's pipeline, which could significantly impact the stock's trajectory.